105 related articles for article (PubMed ID: 21342227)
1. Animal models of toxic epidermal necrolysis.
Azukizawa H
J Dermatol; 2011 Mar; 38(3):255-60. PubMed ID: 21342227
[TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
[TBL] [Abstract][Full Text] [Related]
4. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
5. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
6. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
8. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
[TBL] [Abstract][Full Text] [Related]
9. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
[TBL] [Abstract][Full Text] [Related]
10. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
Abe R
J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
[TBL] [Abstract][Full Text] [Related]
11. Prevention of toxic epidermal necrolysis by regulatory T cells.
Azukizawa H; Sano S; Kosaka H; Sumikawa Y; Itami S
Eur J Immunol; 2005 Jun; 35(6):1722-30. PubMed ID: 15909306
[TBL] [Abstract][Full Text] [Related]
12. Impaired antigen presentation in toxic epidermal necrolysis.
Bagot M; Charue D; Heslan M; Wechsler J; Roujeau JC; Revuz J
Arch Dermatol; 1993 Jun; 129(6):721-7. PubMed ID: 8507074
[TBL] [Abstract][Full Text] [Related]
13. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine.
Friedmann PS; Strickland I; Pirmohamed M; Park BK
Arch Dermatol; 1994 May; 130(5):598-604. PubMed ID: 8179341
[TBL] [Abstract][Full Text] [Related]
14. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
[TBL] [Abstract][Full Text] [Related]
15. Immunological mechanisms of epidermal damage in toxic epidermal necrolysis.
Tohyama M; Hashimoto K
Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):376-82. PubMed ID: 22688730
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement.
Correia O; Delgado L; Ramos JP; Resende C; Torrinha JA
Arch Dermatol; 1993 Apr; 129(4):466-8. PubMed ID: 8466217
[TBL] [Abstract][Full Text] [Related]
17. An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Koh MJ; Tay YK
Curr Opin Pediatr; 2009 Aug; 21(4):505-10. PubMed ID: 19474732
[TBL] [Abstract][Full Text] [Related]
18. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hung CC; Liu WC; Kuo MC; Lee CH; Hwang SJ; Chen HC
Am J Nephrol; 2009; 29(6):633-8. PubMed ID: 19155617
[TBL] [Abstract][Full Text] [Related]
19. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
Murata J; Abe R; Shimizu H
J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
[TBL] [Abstract][Full Text] [Related]
20. Endothelial cell apoptosis in severe drug-induced bullous eruptions.
Verneuil L; Ratajczak P; Allabert C; Leboeuf C; Comoz F; Janin A; Ameisen JC
Br J Dermatol; 2009 Dec; 161(6):1371-5. PubMed ID: 19575754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
